Mall PA
Sub-level B4 · Below the NAD Reactor · Unit 7 does not know about this room

The Research
Basement

No humans allowed.

Peptides and injectable NAD+ the gym won't stop talking about. Every file says what the compound is, what the research actually found (and in what: cells, rats or people), its FDA status, and whether it'll get a tested lifter banned.

The files

Tested lifter? Read this first

USA Powerlifting tests against the WADA Prohibited List. Most of the basement is on it, in and out of competition.

CompoundWADA 2026Risk for a tested lifter
NAD+ (injectable)Substance OK. IV over 100 mL is bannedLow for the substance itself, but a typical clinic IV NAD+ drip is often well over 100 mL, which can be a violation by method without a TUE.
BPC-157Banned · S0High.
TB-500Banned · S2High.
GHK-CuGray areaUncertain.
MOTS-cBanned · S4High.
IpamorelinBanned · S2High.
CJC-1295Banned · S2High.
TesamorelinBanned · S2High without a Therapeutic Use Exemption.
RetatrutideNot named. Gray areaUnclear.
EpitalonLikely caught by S0Likely prohibited under the S0 catch-all; treat it as banned unless Global DRO or USADA says otherwise.
SS-31Not namedProbably low, but unconfirmed; it is not explicitly cleared either.

Check anything before you compete at Global DRO or with your federation. Status as of Oct 1, 2026.

The 2026 peptide paperwork, in order

The FDA spent 2026 reshuffling which peptides pharmacies may compound. Here is what actually happened.

  1. 2023: FDA places BPC-157, TB-500, GHK-Cu (injectable), MOTS-c, Epitalon and others in Category 2 (significant safety risk) of the interim 503A bulks list.
  2. Apr 15, 2026: FDA removes 12 peptides from Category 2 (BPC-157, LL-37, Dihexa, DSIP/emideltide, Epitalon, GHK-Cu injectable, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, TB-500). Removal does not make them eligible for compounding.
  3. Apr 16, 2026: Federal Register notice of the Pharmacy Compounding Advisory Committee (PCAC) meeting for Jul 23-24, 2026.
  4. May 5, 2026: GHK-Cu (non-injectable routes) reinstated to Category 1.
  5. Jul 23-24, 2026: PCAC votes to recommend BPC-157, KPV, TB-500 (8-6), MOTS-c (7-5), Semax and Epitalon (narrow) for the 503A bulks list; rejects emideltide/DSIP (7-6). The recommendations are non-binding and need rulemaking.
  6. Aug-Sep 2026: FDA warning letters to online peptide sellers (posted Sept 1).
  7. Before end of Feb 2027: PCAC review planned for GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II.

Source 1Source 2Source 3Source 4Source 5Source 6

Why this room exists

The gym already talks about these. We'd rather you get the dull, sourced version than a guy in the locker room's version. Commission never changes what a file says.

Want the legal, over-the-counter NAD route instead? The NAD Reactor upstairs ranks NR and NMN capsules. For creatine, the stuff that actually has the research, take the elevator to the Creatine Concourse.